Welcome back to The Drop In, DoubleBlind’s newsletter serving up news, culture, and independent journalism about psychedelics straight to your inbox.

In today’s lead story, Jack Gorsline breaks down the news that the Usona Institute has reportedly filed a New Drug Application with the FDA for its psilocybin treatment for major depressive disorder. The filing has turned up the dial in the space race between Usona, a nonprofit, and its for-profit rival, Compass Pathways. Both are now in the home stretch to bring the first FDA-approved psilocybin drug to market. You can find that story immediately below!

Keep scrolling and you’ll find stories about foraging mushrooms, psychedelics and déjà vu, healing Catholic guilt with psychedelics, and so much more.

Sending blessings of good health,
Mary Carreón
Editor-in-Chief

By Jack Gorsline

UPDATE Nov. 9, 2026: At 6:30AM PT — one hour after we published this story — Compass Pathways announced that it filed its New Drug Application to the FDA for COMP360, its psilocybin drug for depression.

On November 2, 2026, the nonprofit Usona Institute reportedly submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its synthetic psilocybin candidate for major depressive disorder (MDD). First reported by Psychedelic Alpha, the unconfirmed filing — on which Usona declined to comment — sent shares of for-profit competitor Compass Pathways down 28% in a single day. Just a day later, on Nov. 3, Compass announced during its quarterly update that it will complete its own FDA submission for COMP360 in treatment-resistant depression (TRD) within two weeks. 

Compass is targeting a commercial launch in the first half of 2027, pending FDA approval and Drug Enforcement Administration (DEA) rescheduling. While these back-to-back milestones bring psilocybin to the threshold of federal review, projections that COMP360 could cost upwards of $22,000 per dose highlight the massive inequity associated with these treatments caused by steep commercial, clinical, and financial hurdles.

The two frontrunners enter the regulatory home stretch with contrasting clinical datasets and business structures. Compass backs COMP360 with the largest randomized, double-blind clinical program in the history of psilocybin research across two pivotal Phase 3 studies, COMP005 and COMP006. 

According to Compass's 26-week Phase 3 COMP006 readout, 39% of TRD participants in the 25-milligram group achieved a “clinically meaningful reduction” that held through week 26, compared with 25% of single-dose participants in COMP005. That still leaves roughly three in five COMP006 trial participants without sustained relief. 

Usona, meanwhile, is pursuing a broader MDD  label following a 2023 Phase 2 trial of 104 adults comparing a single 25-milligram psilocybin dose against niacin, alongside its Phase 3 uAspire trial, for which topline results have not yet been publicly released.

Where the rivals diverge most sharply is on commercialization, capital structure, and pricing. Compass executives have indicated they intend to price COMP360 in line with Spravato,  Johnson & Johnson's ketamine-derived nasal spray, which costs roughly $50,000 to $65,000 per patient per year. Compass has said it will divide that annual figure by three, its average number of doses to be consumed by patients per year, which works out to roughly $17,000 to $22,000 per dose before multi-hour clinical supervision fees. The Institute for Clinical and Economic Review (ICER) announced Oct. 21 that it will assess COMP360’s clinical effectiveness and value, with a public review set for May 2027. Backed by an extensive patent estate and a sales force it is now building, Compass is positioned to defend those prices.

As Psychedelic Alpha’s Nov. 2 bulletin points out, Usona is operating as a 501(c)(3) medical research organization without Orange Book patent barriers, the FDA-listed protections that keep cheaper competitors off the market. That could theoretically undercut Compass with lower pricing and a wider MDD indication. But the nonprofit currently lacks an active commercial sales force and would likely need a distribution partner to bring its psilocybin drug to market at scale. 

Both submissions are moving at hyper speed thanks to a sweeping federal pivot. On April 18, 2026, President Donald Trump signed an Executive Order directing the Department of Health and Human Services (HHS), the FDA, and the DEA to accelerate treatments for serious mental illness, establish Right to Try access for Schedule I compounds including ibogaine, and allocate at least $50 million in existing Advanced Research Projects Agency for Health (ARPA-H) funds to state psychedelic programs. Six days later, on April 24, the FDA announced that it had awarded Commissioner's National Priority Vouchers to three investigational candidates: Compass's COMP360 (a serotonin-2A agonist) for TRD, Usona's psilocybin drug (a serotonin-2A agonist) for MDD, and Transcend Therapeutics' TSND-201 for post-traumatic stress disorder (PTSD), which was recently acquired by Otsuka. Unlike the psilocybin candidates, TSND-201 (methylone) is an MDMA-like entactogen that acts primarily through monoamine release and reuptake inhibition without significant direct 5-HT2A agonist activity.

The priority voucher pilot aims to compress standard 10-to-12-month FDA review timelines down to just one or two months — though it does not lower the agency's evidentiary bar. Separately, Mike Davis, a psychedelic research proponent and former Usona chief medical officer, was named Center for Drug Evaluation and Research (CDER) deputy director in June 2025, served as acting director starting in May 2026 following Høeg's departure, and was officially appointed permanent CDER Director on September 8, 2026.

“For the millions of people living with depression and PTSD who need more options, a new generation of psychedelics now under FDA review is huge,” a statement from clinic operator Nushama noted. “It is also a signal. With more than 100 clinical trials underway, this is only the beginning of a wave of FDA reviews for mental health indications, and this will be the first of many.”

Whether the U.S. mental healthcare system can absorb supervised psilocybin sessions remains an open question. Compass began laying groundwork in April 2024 through a research collaboration with Journey Clinical to study scalable therapist training and care delivery models.

“The demand is already here,” said Myriam Barthes, co-founder and CEO of Journey Clinical. “Patients want new options, and 95% of Journey Clinical providers have told us they want to offer new psychedelics to their patients. To meet that demand, Journey Clinical is growing its network and has been building toward this milestone for five years. We will be among the first to train clinicians and administer care, ready on day one.” However, that 95% figure reflects internal feedback from a self-selected network of ketamine-assisted psychotherapy providers, rather than readiness across the broader psychiatric workforce.

Larger healthcare systems are watching cautiously. During LifeStance Health’s third-quarter earnings call on Nov. 5, CEO Dave Bourdon, declined to comment on specific psychedelic candidates. He noted that “there's still regulatory, payer reimbursement, and adoption hurdles that remain unresolved.” Still, Bourdon, whose company employs 8,863 clinicians and operates 25 Spravato sites nationwide, signaled that LifeStance is positioning its specialty footprint for future rollouts: “We are monitoring the new psychedelics, new therapies that are coming out, and we have the ability to move faster if that's appropriate.” 

Simultaneously, psychologists petitioned the American Psychological Association in early November to establish a formal Division of Psychedelic Science and Practice to develop ethical and clinical competency frameworks, though the division would not grant licensure or prescriptive authority.

Even if the FDA clears Usona’s drug or COMP360 in early 2027, high per-dose costs and strict Risk Evaluation and Mitigation Strategies (REMS) could bottleneck adoption. Logan Davidson, Director of Policy & Advocacy at Veterans Exploring Treatment Solutions (VETS), wrote for Psychedelics Today that the decisive battles over patient access will unfold not at the FDA, but in state licensing board hearings, legislative committees, and insurance coverage reviews. If commercial payers balk at $18,000-to-$22,000 drug invoices plus facility and therapist monitoring costs, access could rapidly stratify along socioeconomic and geographic lines.

“Usona's submission joins a growing list of psychedelic therapies that are now close to an FDA decision,” said Melissa Lavasani, Founder and Executive Director of the Psychedelic Medicine Coalition (PMC) in an exclusive statement to Psychedelic State(s) of America. “That's real progress, but the hype phase is over, and approval and access are two very different things.“The next chapter is about the less glamorous work [of] making sure these treatments actually reach patients, including people in rural communities and women, who too often face the steepest barriers to mental health care.”

This article was produced in partnership with Psychedelic State(s) of America – a nonprofit-sponsored news organization dedicated to rigorous independent psychedelic journalism. Learn more about PSA’s Media Partnerships Program and the PSA Media Fund here.